


Bepotastine Besilate

Chemical Properties

CAS No. :	190786-44-8
Formula:	C ₂₁ H ₂₅ ClN ₂ O ₃ ·C ₆ H ₆ O ₃ S
Molecular Weight:	547.06
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Bepotastine Besilate (TAU 284) is a non-sedating and selective H1 receptor antagonist (pIC ₅₀ : 5.7).
Targets(IC ₅₀)	Histamine Receptor
In vitro	The flux ratios of [¹⁴ C]Bepotastine (5 μM) in LLC-GA5-COL150 cells are significantly greater than those in LLC-PK1, showing that the B-to-A flux exceeds those in the other direction in LLC-GA5-COL150 cells. Bepotastine stimulates P-gp-mediated ATP hydrolysis with K _m , V _{max} , and V _{max} /K _m values of 1.25 mM, 108 nmol/min/mg protein, and 0.087 mL/min/mg protein, respectively. [2] Bepotastine besilate (100 mM) suppresses Leukotriene B(4) induced Ca(2+) concentration in cultured dorsal root ganglion neurons and cultured neutrophils. [3] Bepotastine (100 μM) dose-dependently inhibits chemotaxis of cultured guinea pig peritoneal eosinophils induced by LTB ₄ . Bepotastine (1 mM) significantly reduces A23187-induced histamine release of cultured rat peritoneal mast cells. [4]
In vivo	Bepotastine (0.8 mg/kg) administrated in WT and P-gp KO mice results in the plasma total concentrations 580 ng/mL and 467 ng/mL at 6 min after dosing, respectively, and the plasma protein binding with 41.1% and 45.9%. The absorption of [¹⁴ C]Bepotastine from the proximal region in the presence and absence of verapamil is 63.0% and 72.4%, respectively, and that from the distal region is 10.9% and 62.7%, respectively. [2] Bepotastine besilate (10 mg/kg) inhibits scratching induced by an intradermal injection of histamine (100 nmol/site), but not serotonin (100 nmol/site). Bepotastine besilate (1 mg/kg-10 mg/kg, oral) dose-dependently suppresses scratching induced by substance P (100 nmol/site) and leukotriene B(4) (0.03 nmol/site). [3] Bepotastine besilate significantly inhibits conjunctival vascular hyperpermeability in a dose-dependent manner in guinea pig allergic conjunctivitis models with maximal effect for Bepotastine besilate 1.5%. [4] Bepotastine (3 mg/kg and 10 mg/kg) effectively inhibits the compound 48/80-induced scratching behavior of BALB/c mice 1 hour after oral administration. Bepotastine (10 mg/kg) also significantly inhibits the scratching behavior and suppresses the serum LTB(4) levels in atopic dermatitis model NC/Nga mice. [5]
Kinase Assay	Isothermal Titration Calorimetry (ITC) of Nucleotide Binding: The titration experiments are performed using the MSC system. In each experiment, 16 aliquots of 15 μL of geldanamycin (300 μM in 1% DMSO) are injected into 1.3 mL of protein (31 μM in 20 mM Tris-HCl, pH 7.5, 1 mM EDTA) at 25 °C, and the resulting data are fit after subtracting

Kinase Assay	the heats of dilution. Heats of dilution are determined in separate experiments from addition of geldanamycin into buffer and buffer into protein. No evidence for binding of DMSO in the nucleotide binding site is observed. Titration data are fit using a nonlinear least-squares curve-fitting algorithm with three floating variables: stoichiometry, binding constant (K_b) $1/K_d$, and change of enthalpy of interaction (ΔH°). Dissociation constants estimated for geldanamycin binding to intact yeast Hsp90 is 1.22 μM , and for binding to Hsp90 N-terminal domain is 0.78 μM . No meaningful heat is observed with binding to the C-terminal fragment.
--------------	---

Solubility Information

Solubility	DMSO: 250 mg/mL (456.99 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), H ₂ O: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 10 mg/mL (18.28 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.31 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.828 mL	9.1398 mL	18.2795 mL
5 mM	0.3656 mL	1.828 mL	3.6559 mL
10 mM	0.1828 mL	0.914 mL	1.828 mL
50 mM	0.0366 mL	0.1828 mL	0.3656 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Da Prada M, et al. J Pharmacol Exp Ther, 1989, 248(1), 400-414.
- Ohashi R, et al. Drug Metab Dispos, 2006, 34(5), 793-799.
- Andoh T, et al. Eur J Pharmacol, 2006, 547(1-3), 59-64.
- Kida T, et al. Exp Eye Res, 2010, 91(1), 85-91.
- Tanizaki H, et al. Int Arch Allergy Immunol, 2008, 145(4), 277-282.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481